FIELD: biochemistry.
SUBSTANCE: described is a group of inventions comprising a siRNA molecule which reduces ORAI1 gene expression when introduced into a cell, use of said siRNA molecule in preparing a drug for treating an eye condition characterized by high expression or activity of the ORAI1 gene, and a pharmaceutical composition comprising said siRNA molecule for treating and/or preventing an eye condition characterized by high expression or activity of ORAI1. In one version, the siRNA molecule contains 19-nucleotide double-stranded region.
EFFECT: invention extends the range of products for specific effect on the ORAI1 gene.
10 cl, 29 dwg, 1 tbl, 32 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR ALLERGIC BRONCHIAL ASTHMA TREATMENT, BASED ON CYTOKINES IL-4 AND IL-13 GENES EXPRESSION INHIBITION USING SIRNA MOLECULES | 2016 |
|
RU2615463C1 |
| METHOD FOR PREVENTING AND TREATING BRONCHIAL ASTHMA, COMPLICATING RESPIRATORY VIRAL INFECTIONS AND OTHER RESPIRATORY INFLAMMATORY DISEASES | 2012 |
|
RU2526146C2 |
| SIRNA AND THEIR USE IN METHODS AND COMPOSITIONS FOR INHIBITING NRARP GENE EXPRESSION | 2016 |
|
RU2738971C2 |
| ANTI-SENSE OLIGONUCLEOTIDES FOR TREATING ALLERGY AND PROLIFERATION OF NEOPLASTIC CELLS | 2005 |
|
RU2416412C2 |
| COMPOSITION FOR INTERLEUKINE-4 CYTOKINE GENE SILENCING | 2014 |
|
RU2563989C1 |
| OLIGONUCLEOTIDE SEQUENCES AIMED AT THE TRANSCRIPTION FACTOR TSC22D4, FOR TREATING INSULIN RESISTANCE | 2016 |
|
RU2723091C2 |
| THERAPEUTIC COMPOSITIONS AND METHODS AGAINST MALIGNANT TUMORS WITH RNAi MOLECULES DIRECTED AGAINST Hsp47 | 2015 |
|
RU2756253C2 |
| SORAFENIB-BASED COMBINATION THERAPY FOR HEPATOCELLULAR CARCINOMA | 2022 |
|
RU2800071C1 |
| iRNA-MEDIATED INHIBITION OF TUMOUR NECROSIS FACTOR-( RELATED CONDITIONS | 2007 |
|
RU2469090C2 |
| INHIBITING OF STAT-1 | 2002 |
|
RU2311910C2 |
